EMEA-002651-PIP01-19
Key facts
| Active substance |
glibenclamide
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0043/2020
|
| PIP number |
EMEA-002651-PIP01-19
|
| Pharmaceutical form(s) |
Powder for solution for injection
|
| Condition(s) / indication(s) |
Treatment of large hemispheric infarction
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Biogen Idec Limited
Tel. +44 1628512586 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|